On Wednesday shares of Repros Therapeutics Inc. (NASDAQ:RPRX) closed at $9.13. On 6 April, Repros Therapeutics Inc. (NASDAQ:RPRX) announced that the European Medicines Agency (EMA) has informed the Company, through Repros’ wholly owned subsidiary, that its enclomiphene citrate capsules are eligible for submission for a centralized marketing authorization application (MAA) as a New Active Substance. Not all products are eligible for the centralized procedure and the Company was able to provide data to indicate significant differences between enclomiphene citrate and clomiphene.
On Track Innovations Ltd. (NASDAQ:OTIV) in last trading activity increased 2.60% to close at $1.58. Company weekly performance is 7.48% while its quarterly performance stands at -12.71%. On Track Innovations Ltd. (NASDAQ:OTIV) is -68.40% away from its 52 week high. Stock analysts at Northland Securities cut their price target on shares of On Track Innovations Ltd. (NASDAQ:OTIV) from $4.00 to $3.50 in a report issued on Tuesday. The firm currently has an “outperform” rating on the stock. Northland Securities’ price target indicates a potential upside of 134.90% from the stock’s previous close.
On last trading day The Spectranetics Corporation (NASDAQ:SPNC) increased 0.09% to close at $34.56. Its volatility for the week is 1.80% while volatility for the month is 2.54%. SPNC’s sales growth for past 5 years was 12.30% and its EPS growth for past 5 years was -19.00%. The Spectranetics Corporation (NASDAQ:SPNC) monthly performance is -4.48%. The Spectranetics Corporation (NASDAQ:SPNC) announced that the Company will release 2015 first quarter financial results after market close on Thursday, April 23, 2015.
Continental Building Products, Inc. (NYSE:CBPX) has 0.20% insider ownership while its institutional ownership stands at 97.80%. In last trading activity company’s stock closed at $22.76. Continental Building Products, Inc. (NYSE:CBPX) announced that the Company will release first quarter 2015 financial results after the market closes on Wednesday, May 6, 2015.
On last trading day DepoMed Inc. (NASDAQ:DEPO) increased 3.04% to close at $26.43. Its volatility for the week is 3.60% while volatility for the month is 4.25%. DEPO’s sales growth for past 5 years was 46.60% and its EPS growth for past 5 years was 46.60%. DepoMed Inc. (NASDAQ:DEPO) monthly performance is 7.00%. On 13 April, DepoMed Inc. (NASDAQ:DEPO) announced it has entered into a settlement agreement with Actavis, Inc. in Depomed’s patent infringement litigation related to Actavis’s Abbreviated New Drug Application seeking approval to market generic versions of Depomed’s Gralise® (gabapentin) 300 mg and 600 mg tablets.